NEWS CENTER

Position:

Group Announcement

Media reports

Group News

The company’s brand value and brand strength have ranked among the top 30 in the pharmaceutical industry.

Category:

Group Announcement

Time：2018-11-08

Release of 2018 China Brand Value Evaluation Information On May 9, the “2018 China Brand Value Evaluation Information” event—jointly released by the China Brand Building Promotion Association, the Economic Daily, the China Council for the Promotion of International Trade, and the China Asset Appraisal Association—was held in Shanghai. In the “2018 Brand Value Evaluation Release List,” a total of 46 pharmaceutical and healthcare brands were listed. Among them, our company ranked 21st on the list with a brand strength score of 884 and a brand value of 3.467 billion yuan, firmly establishing itself as the No. 1 domestic brand in the large-volume parenteral solutions manufacturing sector and fully demonstrating its strength in the pharmaceutical market.

Release of the 2018 China Brand Value Evaluation Report

On May 9, the “2018 China Brand Value Evaluation Information” event—jointly released by the China Brand Building Promotion Association, the Economic Daily, the China Council for the Promotion of International Trade, and the China Asset Appraisal Association—was held in Shanghai. In the “2018 Brand Value Evaluation Release List,” a total of 46 pharmaceutical and healthcare brands made the list. Among them, our company ranked 21st with a brand strength score of 884 points and a brand value of 3.467 billion yuan, firmly establishing itself as the No. 1 brand in China’s large-volume parenteral solutions production sector and fully demonstrating the broad recognition that the pharmaceutical market has for our company’s brand.

This year’s release of China Brand Value Assessment marks the fifth consecutive year that China has hosted and published such an event. The scope of this brand assessment covers four major areas: corporate brands, product brands, regional brands, and independently innovative brands. The assessment released top 50 rankings across multiple industries and sectors, encompassing 1,346 companies and 718 brands.

The eligibility criteria for this brand evaluation are quite stringent: manufacturing enterprises recommended for consideration must have achieved continuous profitability over the past three years, with an average annual profit and tax contribution of no less than 100 million yuan. In accordance with the principle of voluntary participation by enterprises, the China Brand Building Promotion Association will conduct this brand value assessment based on relevant standards such as ISO 10668. Following the assessment results, the Association will coordinate with authoritative media to publicly release the findings.

In recent years, the company has adhered to the business philosophy of "Integrity First, Quality-Driven Customer Care," taking the enhancement of a comprehensive quality mindset as its key driver to promote the development of both product and corporate brands, thus forging a path of quality-brand development uniquely characteristic of Siyao. After 70 years of relentless efforts and brand-building, the company’s large-volume parenteral solutions have earned widespread acclaim in both domestic and international markets. Among these, flexible-bag infusions account for over 50% of the domestic market share. The products have successfully passed quality certifications and audits conducted by multiple countries, including Australia’s TGA and the Netherlands’ IDA, and are now distributed across China as well as 80 other countries and regions. The company has received numerous honors, including the National High-Quality Product Award, Provincial Famous Brand Product Award, and Consumer-Trustworthy Product Award. The company’s “Shimen” trademark was among the earliest to be recognized as a well-known trademark in China’s large-volume parenteral solution manufacturing sector. Currently, the company’s annual production capacity for large-volume parenteral solutions reaches 2 billion bottles (bags). In terms of production scale, quality standards, process technology, and brand influence, the company holds a leading position within the domestic industry. It has also been ranked among the top 100 Chinese pharmaceutical enterprises in terms of overall strength and listed among the top 10 outstanding brands in China’s chemical pharmaceutical preparations export sector, establishing itself as a major domestic base for the production, R&D, and export of high-capacity injectables.

Qu Jiguang, Chairman of the company, stated: “We will further accelerate our internationalization process, focusing on cultivating a group of renowned products with strong international competitiveness and high added value. We will continue to strengthen and expand our national pharmaceutical brands, building a comprehensive pharmaceutical group that integrates modernization and internationalization. We will remain committed to our brand philosophy of being a first-class enterprise, producing first-class pharmaceuticals, and providing first-class services, thereby boosting Chinese brands onto the global stage, enabling the Siyao brand to gain a foothold in the international market, better serving human health and well-being, and creating a century-old powerhouse.”

Keywords:

Secretary of the Provincial Party Committee Wang Dongfeng presented Chairman Qu Jiguang with the certificate for the First Prize of the Science and Technology Progress Award.

Yin Dianshu was awarded the “Provincial May Day Labor Medal.”

Secretary of the Provincial Party Committee Wang Dongfeng presented Chairman Qu Jiguang with the certificate for the First Prize of the Science and Technology Progress Award.

Yin Dianshu was awarded the “Provincial May Day Labor Medal.”